Hexarelin

Hexarelin is a synthetic growth hormone-releasing peptide studied mainly as an endocrine secretagogue. Early human studies describe it as a hexapeptide capable of producing acute, dose-dependent growth hormone release after intravenous administration, with additional work exploring intranasal, oral, and subcutaneous exposure ^[1][2][3]. The human evidence base is small and mostly older; it supports pharmacodynamic activity, not modern therapeutic efficacy. Hexarelin is also not fully GH-specific: comparative and sleep studies reported stimulation of prolactin, ACTH, and cortisol, which is important for safety framing ^[4][5]. Cardiovascular research is mixed in evidentiary strength. A small human physiology study reported a short-lived increase in left ventricular ejection fraction after acute dosing, while rat myocardial infarction models suggested improved cardiac function after treatment ^[6][7]. These findings should be clearly separated from proven clinical benefit. Hexarelin content should emphasize research context, limited modern evidence, and non-approval/no-medical-advice positioning.

Growth Hormone Secretagogue Activity

Hexarelin has human pharmacodynamic evidence as a growth hormone secretagogue. In a placebo-controlled dose-response study, intravenous hexarelin increased plasma growth hormone concentrations in healthy men, with peak effects occurring after administration ^[1].

Aging and GH-IGF Axis Research

Small studies in older adults suggest that short-term intermittent dosing can preserve acute GH responsiveness, but longer-term therapy showed partial reversible attenuation of GH response and limited impact on downstream IGF-axis markers ^[2][3]. These findings support research interest, not a treatment claim.

Cardiovascular Research Signals

A small acute human study reported a transient increase in left ventricular ejection fraction after hexarelin, and a rat post-myocardial-infarction model reported improved cardiac function ^[6][7]. The animal data should not be treated as human efficacy evidence.

Limited and Older Human Evidence

Hexarelin should not be presented as an approved therapy or medical advice. The human evidence base is small, much of it predates current trial-registration norms, and the available studies are mostly endocrine challenge or physiology studies rather than modern outcome trials ^[1][2][3][6].

Off-Target Endocrine Effects

Hexarelin is not selective only for growth hormone release. Human studies reported prolactin, ACTH, and cortisol responses, and nighttime dosing altered sleep architecture while increasing several hormones ^[4][5]. These effects should be described as safety-relevant research observations.

Chronic Use Uncertainty

Longer-term human data are limited. One 16-week study found partial, reversible attenuation of GH response and little consistent downstream biological effect, leaving chronic dosing, durability, and risk-benefit questions unresolved ^[3].

Translational Limits

Cardiovascular findings require careful wording. Acute human physiology and rat myocardial infarction data are hypothesis-generating and do not establish clinical cardioprotection, heart-failure treatment, or safety in broader human populations ^[6][7].